Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -0.01 is 280% below its 5-year average of 0.01, near the low end of its 5-year range (-0.01–0.02).
As of the fiscal period ended Tuesday, June 30, 2026. 261.56% below its 12-month average of 0.01.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -0.01.
DEBT TO EQUITY RATIO
-0.01
DEBT TO EQUITY RATIO AVG TTM
0.01
DEBT TO EQUITY RATIO AVG 3Y
0.01
DEBT TO EQUITY RATIO AVG 5Y
0.01
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-261.56%
CURRENT VS 3Y AVG
-228.39%
CURRENT VS 5Y AVG
-280.12%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-111.22%
vs the sector median at left
Lantern Pharma Inc.
Market Cap
$12.17M
Debt to Equity Ratio
-0.01
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$12.06M
Debt to Equity Ratio
0.05
TTM Avg
0.04
3Y Avg
0.04
5Y Avg
0.03
Market Cap
$12.48M
Debt to Equity Ratio
N/A
TTM Avg
0.93
3Y Avg
0.49
5Y Avg
0.33
Market Cap
$11.77M
Debt to Equity Ratio
1.10
TTM Avg
0.92
3Y Avg
1.14
5Y Avg
0.73
Market Cap
$12.58M
Debt to Equity Ratio
N/A
TTM Avg
1.01
3Y Avg
1.00
5Y Avg
0.90
Market Cap
$12.69M
Debt to Equity Ratio
0.00
TTM Avg
0.85
3Y Avg
0.52
5Y Avg
0.35
Market Cap
$12.78M
Debt to Equity Ratio
0.01
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$11.55M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.01
5Y Avg
0.01
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lantern Pharma Inc. (LTRN) | $12.17M | -0.01 | 0.01 | 0.01 | 0.01 |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.06M | 0.05 | 0.04 | 0.04 | 0.03 |
| Biofrontera Inc. (BFRI)vs › | $11.93M | 1.26 | 0.85 | 0.72 | 0.48 |
| Dare Bioscience, Inc. (DARE)vs › | $12.48M | N/A | 0.93 | 0.49 | 0.33 |
| IRIDEX Corporation (IRIX)vs › | $11.77M | 1.10 | 0.92 | 1.14 | 0.73 |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.58M | N/A | 1.01 | 1.00 | 0.90 |
| Passage Bio, Inc. (PASG)vs › | $12.69M | 0.00 | 0.85 | 0.52 | 0.35 |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.78M | 0.01 | 0.00 | 0.00 | 0.00 |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.55M | 0.00 | 0.00 | 0.01 | 0.01 |
| Cytosorbents Corporation (CTSO)vs › | $12.79M | N/A | 3.67 | 2.17 | 1.48 |
Debt/Equity
-0.01
Current Ratio
1.96
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -0.01 |
| 2026-03-31 | 0.02 |
| 2025-12-31 | 0.01 |
| 2025-09-30 | 0.01 |
| 2025-06-30 | 0.01 |
| 2025-03-31 | 0.01 |
| 2024-12-31 | 0.01 |
| 2024-09-30 | 0.01 |
| 2024-06-30 | 0.01 |
| 2024-03-31 | 0.01 |
| 2023-12-31 | 0.01 |
| 2023-09-30 | 0.01 |
| 2023-06-30 | 0.01 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 0.00 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | 0.00 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.00 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | 0.01 |
| 2020-09-30 | 0.01 |
| 2020-06-30 | 0.01 |
| 2020-03-31 | 0.10 |
| 2019-12-31 | 0.00 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
